Evercore Wealth Management LLC Sells 1,327 Shares of Eli Lilly and Company (NYSE:LLY)

Evercore Wealth Management LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 51,279 shares of the company’s stock after selling 1,327 shares during the period. Evercore Wealth Management LLC’s holdings in Eli Lilly and were worth $14,685,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the stock. First Manhattan Co. increased its holdings in shares of Eli Lilly and by 4.1% in the 1st quarter. First Manhattan Co. now owns 131,735 shares of the company’s stock worth $37,725,000 after buying an additional 5,223 shares during the last quarter. First Republic Investment Management Inc. increased its holdings in shares of Eli Lilly and by 7.5% in the 1st quarter. First Republic Investment Management Inc. now owns 348,458 shares of the company’s stock worth $99,788,000 after buying an additional 24,328 shares during the last quarter. Forum Financial Management LP increased its holdings in shares of Eli Lilly and by 6.6% in the 1st quarter. Forum Financial Management LP now owns 8,572 shares of the company’s stock worth $2,454,000 after buying an additional 527 shares during the last quarter. Gluskin Sheff & Assoc Inc. bought a new position in shares of Eli Lilly and in the 1st quarter worth $4,316,000. Finally, Guardian Wealth Advisors LLC NC bought a new position in shares of Eli Lilly and in the 1st quarter worth $260,000. Institutional investors own 82.45% of the company’s stock.

Eli Lilly and Trading Down 0.8 %

NYSE:LLY opened at $315.22 on Tuesday. The company has a 50-day moving average price of $317.94 and a 200-day moving average price of $301.86. Eli Lilly and Company has a 12 month low of $220.20 and a 12 month high of $335.33. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70. The stock has a market cap of $299.51 billion, a price-to-earnings ratio of 50.27, a P/E/G ratio of 2.16 and a beta of 0.38.

Eli Lilly and (NYSE:LLYGet Rating) last posted its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The company had revenue of $6.49 billion during the quarter, compared to analysts’ expectations of $6.85 billion. During the same period in the prior year, the business posted $1.87 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 7.97 EPS for the current year.

Eli Lilly and Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 9th. Stockholders of record on Monday, August 15th were given a $0.98 dividend. The ex-dividend date was Friday, August 12th. This represents a $3.92 annualized dividend and a dividend yield of 1.24%. Eli Lilly and’s dividend payout ratio is 62.52%.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. UBS Group increased their price target on shares of Eli Lilly and to $335.00 and gave the stock an “outperform” rating in a report on Wednesday, July 27th. JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. StockNews.com lowered shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating in a report on Friday, August 5th. Citigroup increased their target price on shares of Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. Finally, SVB Leerink started coverage on shares of Eli Lilly and in a report on Monday, May 23rd. They set an “outperform” rating and a $341.00 target price on the stock. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $330.44.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $306.84, for a total value of $64,436,400.00. Following the completion of the transaction, the insider now directly owns 104,623,810 shares in the company, valued at approximately $32,102,769,860.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $306.84, for a total value of $64,436,400.00. Following the completion of the transaction, the insider now directly owns 104,623,810 shares in the company, valued at approximately $32,102,769,860.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Alonzo Weems sold 656 shares of the stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $304.50, for a total transaction of $199,752.00. Following the completion of the transaction, the senior vice president now owns 8,136 shares of the company’s stock, valued at $2,477,412. The disclosure for this sale can be found here. Insiders sold a total of 753,125 shares of company stock worth $242,744,201 in the last three months. 0.12% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.